Nurse Practitioner · Scottsdale, AZ
NPI
1447814520
Since 2019
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
13400 E Shea Blvd
Scottsdale, AZ, 85259
Phone (480) 301-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$70K
940 services
Medicare patients, 2024
384
Average age 76
Drug cost, 2024
$5.8M
724 prescriptions
Company payments, 2025
$540
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jennifer T Andres was code 99214 (office e&m - established), 540 times for 279 patients. In total Jennifer T Andres billed 940 services in 7 codes, and Medicare paid $70K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-09-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 540 | 279 | $76.41 | $41K |
| 99215 Office E&M - Established | Office | 187 | 131 | $112.80 | $21K |
| 99213 Office E&M - Established | Office | 100 | 75 | $55.30 | $5,530 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 98 | 49 | $10.34 | $1,013 |
By year: 2022 $15K for 927 services; 2023 $23K for 250 services; 2024 $70K for 940 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jennifer T Andres prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 153 prescriptions and refills. In total Jennifer T Andres wrote 724 Medicare prescriptions that cost $5.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 153 | 157 | 23 | $2.5M |
| Hydroxyurea Generic | 133 | 342 | 44 | $3,366 |
| Pegasys Peginterferon Alfa-2a | 84 | 84 | 14 | $296K |
| Ojjaara Momelotinib Dihydrochloride | 47 | 47 | Under 11 | $1.3M |
| Besremi Ropeginterferon Alfa-2b-Njft | 38 | 38 | Under 11 | $514K |
| Acyclovir Generic | 37 | 92 | 14 | $601 |
| Imatinib Mesylate Generic | 30 | 30 | Under 11 | $80K |
| Prochlorperazine Maleate Generic | 16 | 16 | 11 | $270 |
| Eliquis Apixaban | 15 | 27 | Under 11 | $16K |
| Fluconazole Generic | 14 | 20 | Under 11 | $1,055 |
| Gleevec Imatinib Mesylate | 14 | 16 | Under 11 | $248K |
Brand drugs: 380 claims; generic drugs: 344 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jennifer T Andres $540 ($540 in general payments such as food, travel and fees) from 5 companies. The largest payer was Sobi, Inc with $228.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.